$364 Million is the total value of Sands Capital Ventures, LLC's 19 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 5.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PATH | UIPATH INC | $69,336,000 | -15.7% | 3,811,779 | 0.0% | 19.04% | +10.7% | |
DICE THERAPEUTICS, INC. | $48,872,000 | -18.9% | 3,148,970 | 0.0% | 13.42% | +6.6% | ||
DASH | DOORDASH INC | $38,595,000 | -45.2% | 601,454 | 0.0% | 10.60% | -28.0% | |
NU HOLDINGS LTD. | $34,172,000 | -51.6% | 9,136,835 | 0.0% | 9.38% | -36.3% | ||
SAMSARA, INC. | $30,296,000 | -30.3% | 2,712,256 | 0.0% | 8.32% | -8.4% | ||
SNOW | SNOWFLAKE INC | $29,845,000 | -39.3% | 214,621 | 0.0% | 8.20% | -20.2% | |
KRTX | Sell | KARUNA THERAPEUTICS, INC. | $21,873,000 | -35.6% | 172,895 | -35.5% | 6.01% | -15.4% |
TXG | New | 10X Genomics, Inc. | $21,800,000 | – | 481,770 | +100.0% | 5.99% | – |
CINCOR PHARMA, INC. | $17,898,000 | +7.4% | 950,000 | 0.0% | 4.92% | +41.2% | ||
ABOS | ACUMEN PHARMACEUTICALS, INC | $16,060,000 | +20.2% | 3,417,075 | 0.0% | 4.41% | +58.0% | |
OLK | Buy | OLINK HOLDING AB | $10,724,000 | +42.7% | 705,514 | +65.8% | 2.94% | +87.6% |
MASS | 908 DEVICES INC | $6,721,000 | +8.3% | 326,427 | 0.0% | 1.85% | +42.4% | |
TARS | TARSUS PHARMACEUTICALS INC | $3,796,000 | -13.2% | 260,000 | 0.0% | 1.04% | +14.0% | |
RGEN | REPLIGEN CORP. | $3,661,000 | -13.7% | 22,544 | 0.0% | 1.00% | +13.4% | |
SAMSARA, INC. | $3,641,000 | -30.3% | 326,000 | 0.0% | 1.00% | -8.3% | ||
TSHA | TAYSHA GENE THERAPIES INC | $2,697,000 | -42.9% | 724,873 | 0.0% | 0.74% | -24.9% | |
CANDEL THERAPEUTICS, INC | $2,630,000 | -36.4% | 811,737 | 0.0% | 0.72% | -16.3% | ||
SPRB | SPRUCE BIOSCIENCES INC | $1,369,000 | -13.5% | 787,007 | 0.0% | 0.38% | +13.6% | |
ABSCI CORP. | $192,000 | -60.6% | 57,804 | 0.0% | 0.05% | -48.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
UIPATH INC | 9 | Q3 2023 | 30.2% |
DOORDASH INC | 9 | Q3 2023 | 19.6% |
SNOWFLAKE INC | 9 | Q3 2023 | 14.4% |
ACUMEN PHARMACEUTICALS, INC | 9 | Q3 2023 | 10.0% |
908 DEVICES INC | 9 | Q3 2023 | 1.8% |
TARSUS PHARMACEUTICALS INC | 9 | Q3 2023 | 1.4% |
TAYSHA GENE THERAPIES INC | 9 | Q3 2023 | 2.0% |
CANDEL THERAPEUTICS, INC | 9 | Q3 2023 | 1.3% |
SPRUCE BIOSCIENCES INC | 9 | Q3 2023 | 0.7% |
ABSCI CORPORATION | 9 | Q3 2023 | 0.1% |
View Sands Capital Ventures, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-15 |
13F-HR | 2023-05-12 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-09 |
View Sands Capital Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.